AR048055A1 - Derivados de pirimidina como inhibidores de dipeptidil peptidasa - Google Patents
Derivados de pirimidina como inhibidores de dipeptidil peptidasaInfo
- Publication number
- AR048055A1 AR048055A1 ARP040104929A ARP040104929A AR048055A1 AR 048055 A1 AR048055 A1 AR 048055A1 AR P040104929 A ARP040104929 A AR P040104929A AR P040104929 A ARP040104929 A AR P040104929A AR 048055 A1 AR048055 A1 AR 048055A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- substituted
- heterocycloalkyl
- cycloalkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 4
- 125000005243 carbonyl alkyl group Chemical group 0.000 abstract 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000004963 sulfonylalkyl group Chemical group 0.000 abstract 3
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 238000000926 separation method Methods 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- -1 C1-10 perhaloalkyl Chemical group 0.000 abstract 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 abstract 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 235000011941 Tilia x europaea Nutrition 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000006843 cycloalkyl-C1-5-alkyl Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 239000004571 lime Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
Abstract
Compuestos, composiciones farmacéuticas, conjuntos de elementos y métodos para usar con DPP-IV y otras proteasas 59. Reivindicacion 1: Un compuesto caracterizado porque comprende la formula general (1) donde: M es N o CR4; Q1 y Q2 se seleccionan cada uno independientemente del grupo que consiste en CO, CS, SO, SO2, y C=NR9; R2 es H o se selecciona del grupo que consiste en alquilo C1-10, cicloalquilo C3-12, cicloalquil C3-12-alquilo C1-5, heterocicloalquil C3-12-alquilo C1-5, heterocicloalquilo C3-12, arilalquilo C1-10, heteroarilalquilo C1-5, bicicloarilo C9-12, heterobicicloarilo C4-12, heterobicicloaril C4-12-alquilo C1-5, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, iminoalquilo C1-3, amino, arilo, heteroarilo, hidroxilo, alcoxilo, ariloxilo, heteroariloxilo, un grupo carbonilo, un grupo imino, un grupo sulfonilo y un grupo sulfinilo, cada uno sustituido o no sustituido; R3 se selecciona del grupo que consiste en perhaloalquilo C1-10, amino, alquilo C1-10, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, arilo, heteroarilo, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, iminoalquilo C1-3, hidroxilo, alcoxilo, ariloxilo, heteroariloxilo, un grupo carbonilo, un grupo imino, un grupo sulfonilo y un grupo sulfinilo, cada uno sustituido o n o sustituido, y un anillo sustituido o no sustituido de 3, 4, 5, 6 o 7 miembros; R4 es H se selecciona del grupo que consiste en halo, perhaloalquilo C1-10, amino, ciano, tilo, alquilo C1-10, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, arilo, heteroarilo, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, iminoalquilo C1-3, hidroxilo, alcoxilo, ariloxilo, heteroariloxilo, un grupo carbonilo, un grupo imino, un grupo sulfonilo, un grupo sulfinilo, cada uno sustituido o no sustituido; R9 es H o se selecciona del grupo que consiste en alquilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, bicicloarilo, y heterobicicloarilo, cada uno sustituido o no sustituido; L es un conector que proporciona una separacion de 1, 2 o 3 átomos entre X y el anillo al que está unido L, donde los átomos del conector que proporcionan la separacion se seleccionan del grupo que consiste en átomos de C; O; N y S; y X se selecciona del grupo que consiste en alquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, arilalquilo C1-10, heteroarilalquilo C1-5, bicicloarilo C9-12, heterobicicloarilo C4-12, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, iminoalquilo C1-3, amino, arilo, heteroarilo, hidroxilo, alcoxilo, ariloxilo, heteroariloxilo, alquenilo, alquinilo, un grupo carbonilo, ciano, un grupo imino, un grupo sulfonilo y un grupo sulfinilo, cada uno sustituido o no sustituido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55357104P | 2004-03-15 | 2004-03-15 | |
| US62952404P | 2004-11-18 | 2004-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048055A1 true AR048055A1 (es) | 2006-03-29 |
Family
ID=34930979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104929A AR048055A1 (es) | 2004-03-15 | 2004-12-28 | Derivados de pirimidina como inhibidores de dipeptidil peptidasa |
Country Status (36)
| Country | Link |
|---|---|
| US (8) | US7807689B2 (es) |
| EP (1) | EP1586571B3 (es) |
| JP (3) | JP3895349B2 (es) |
| KR (2) | KR101071390B1 (es) |
| CN (7) | CN102079743B (es) |
| AR (1) | AR048055A1 (es) |
| AT (1) | ATE401320T1 (es) |
| AU (1) | AU2004318013B8 (es) |
| BE (1) | BE2014C010I2 (es) |
| BR (1) | BRPI0418639B8 (es) |
| CA (1) | CA2559302C (es) |
| CR (1) | CR8595A (es) |
| CY (2) | CY1108393T1 (es) |
| DE (1) | DE602004015067D1 (es) |
| DK (1) | DK1586571T6 (es) |
| EA (1) | EA013427B1 (es) |
| ES (1) | ES2310704T7 (es) |
| FR (1) | FR14C0013I2 (es) |
| GE (1) | GEP20094679B (es) |
| HR (1) | HRP20080509T4 (es) |
| HU (1) | HUS1400007I1 (es) |
| IL (2) | IL177629A (es) |
| LU (1) | LU92374I2 (es) |
| MA (1) | MA28469B1 (es) |
| MX (1) | MXPA06010571A (es) |
| MY (1) | MY146290A (es) |
| NL (1) | NL300640I2 (es) |
| NO (2) | NO332232B1 (es) |
| NZ (1) | NZ549716A (es) |
| PL (1) | PL1586571T6 (es) |
| PT (1) | PT1586571E (es) |
| RS (1) | RS50621B2 (es) |
| SI (1) | SI1586571T1 (es) |
| TW (2) | TWI344962B (es) |
| UA (1) | UA85871C2 (es) |
| WO (1) | WO2005095381A1 (es) |
Families Citing this family (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| KR20050122220A (ko) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| BRPI0413452A (pt) | 2003-08-13 | 2006-10-17 | Takeda Pharmaceutical | composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv |
| WO2005030751A2 (en) * | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| CN102079743B (zh) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| US7931661B2 (en) * | 2004-06-14 | 2011-04-26 | Usgi Medical, Inc. | Apparatus and methods for performing transluminal gastrointestinal procedures |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1931350B2 (en) * | 2005-09-14 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
| GEP20135838B (en) * | 2005-09-14 | 2013-06-10 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors usage at diabetes treatment |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| ZA200806143B (en) * | 2005-12-28 | 2009-11-25 | Takeda Pharmaceutical | Therapeutic agent for diabetes |
| AU2006330332B2 (en) * | 2005-12-28 | 2012-03-08 | Takeda Pharmaceutical Company Limited | Therapeutic agent for diabetes |
| CN101495464B (zh) * | 2005-12-29 | 2014-03-05 | 詹森药业有限公司 | 激肽原1受体拮抗剂 |
| WO2007112368A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| AU2007235876A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| KR101257378B1 (ko) | 2006-04-19 | 2013-04-23 | 삼진제약주식회사 | 항바이러스성 피리미딘디온 유도체 및 이의 제조 방법 |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| DE602007013567D1 (de) * | 2006-08-16 | 2011-05-12 | Novartis Ag | Verfahren zur herstellung fester dispersionen von midostaurin |
| MX2009002282A (es) | 2006-09-07 | 2009-03-20 | Nycomed Gmbh | Tratamiento de combinacion para diabetes mellitius. |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| KR102062824B1 (ko) * | 2006-09-13 | 2020-01-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도 |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| DK2107905T3 (da) * | 2007-02-01 | 2011-01-31 | Takeda Pharmaceutical | Fast sammensætning omfattende alogliptin og pioglitazon |
| ES2639854T3 (es) * | 2007-02-01 | 2017-10-30 | Takeda Pharmaceutical Company Limited | Preparación de comprimidos sin causar problemas de fabricación de comprimidos |
| CA2680684A1 (en) * | 2007-03-13 | 2008-09-25 | Takeda Pharmaceutical Company Limited | Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1 (2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile |
| US8093236B2 (en) * | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| US8927504B2 (en) | 2007-04-03 | 2015-01-06 | Mitsubishi Tanabe Pharma Corporation | Combined use of dipeptidyl peptidase 4 inhibitor and sweetener |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| EA021544B1 (ru) | 2007-06-04 | 2015-07-30 | Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити | Триарильные соединения и фармацевтические композиции, их содержащие |
| UA98799C2 (ru) | 2007-07-19 | 2012-06-25 | Такеда Фармасьютикал Компани Лимитед | Твердый препарат, включающий алоглиптин и гидрохлорид метформина |
| CL2008002427A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| US20090082376A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched alogliptin |
| JP2010540635A (ja) * | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
| CN101883556B (zh) | 2007-11-02 | 2013-05-29 | 艾克若克斯Dds有限公司 | 激素和类固醇的透皮递送系统 |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| WO2009099171A1 (ja) * | 2008-02-07 | 2009-08-13 | Takeda Pharmaceutical Company Limited | 医薬 |
| WO2009099172A1 (ja) * | 2008-02-07 | 2009-08-13 | Takeda Pharmaceutical Company Limited | 医薬 |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| WO2009140685A2 (en) | 2008-05-16 | 2009-11-19 | Bristol-Myers Squibb Company | Methods for identifying subjects with an increased likelihood of responding to dpp-iv inhibitors |
| US20170149600A9 (en) | 2008-05-23 | 2017-05-25 | Nader Asghari Kamrani | Music/video messaging |
| US20110066940A1 (en) | 2008-05-23 | 2011-03-17 | Nader Asghari Kamrani | Music/video messaging system and method |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| KR101657960B1 (ko) | 2008-08-15 | 2016-09-20 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체 |
| JP2012502081A (ja) | 2008-09-10 | 2012-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連症状の治療のための組み合わせ治療 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| RU2572529C2 (ru) * | 2008-12-23 | 2016-01-20 | Сандоз Аг | Кристаллическая форма органического соединения |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| CN102387795A (zh) | 2009-02-13 | 2012-03-21 | 贝林格尔.英格海姆国际有限公司 | 包含dpp-4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
| JP2012521411A (ja) * | 2009-03-26 | 2012-09-13 | マピ ファーマ リミテッド | アログリプチンの調製プロセス |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| JP5732394B2 (ja) | 2009-07-28 | 2015-06-10 | 武田薬品工業株式会社 | 錠剤 |
| WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| EP2308847B1 (en) | 2009-10-09 | 2014-04-02 | EMC microcollections GmbH | Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
| CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
| CA2784799C (en) | 2009-12-30 | 2014-06-10 | Shanghai Fochon Pharmaceutical Co Ltd | Certain dipeptidyl peptidase inhibtors |
| AU2011209848B2 (en) | 2010-01-28 | 2016-01-28 | Avery Dennison Corporation | Label applicator belt system |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| ES2481823T3 (es) | 2010-03-10 | 2014-07-31 | Probiodrug Ag | Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5) |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| CN103068392A (zh) * | 2010-05-12 | 2013-04-24 | Mapi医药公司 | 苯甲酸阿格列汀的多晶形物 |
| CN102260265B (zh) | 2010-05-24 | 2015-09-02 | 上海阳帆医药科技有限公司 | 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途 |
| EP3124041A1 (en) | 2010-06-24 | 2017-02-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| RU2427373C1 (ru) | 2010-11-08 | 2011-08-27 | Виктор Вениаминович Тец | Средство для индукции эндогенного интерферона |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| DK2670486T3 (en) | 2011-01-31 | 2016-05-17 | Cadila Healthcare Ltd | TREATMENT FOR LIPODYSTROPHY |
| EP2680851B1 (en) | 2011-03-03 | 2016-08-17 | Merck Sharp & Dohme Corp. | Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| HUE061596T2 (hu) | 2011-07-15 | 2023-07-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben |
| WO2013046229A1 (en) * | 2011-09-26 | 2013-04-04 | Hetero Research Foundation | Novel salts of alogliptin |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CN103044391B (zh) * | 2011-10-13 | 2015-11-25 | 中国科学院广州生物医药与健康研究院 | 一种高效的dpp-iv抑制剂 |
| MD20140044A2 (ro) | 2011-11-11 | 2014-08-31 | Pfizer Inc. | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| TWI580444B (zh) | 2012-06-05 | 2017-05-01 | 武田藥品工業股份有限公司 | 固態製劑 |
| CN103664801A (zh) * | 2012-08-30 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种制备阿格列汀的方法 |
| CN103788070B (zh) * | 2012-10-26 | 2017-10-20 | 南京华威医药科技开发有限公司 | Dpp‑4抑制剂类多聚物 |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| MY180160A (en) | 2013-04-22 | 2020-11-23 | Cadila Healthcare Ltd | A novel composition for nonalcoholic fatty liver disease (nafld) |
| ES2889916T3 (es) | 2013-05-30 | 2022-01-14 | Cadila Healthcare Ltd | Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
| IN2013MU02470A (es) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| IN2013MU02905A (es) | 2013-09-06 | 2015-07-03 | Cadila Healthcare Ltd | |
| EP3046912A1 (de) | 2013-09-16 | 2016-07-27 | Bayer Pharma Aktiengesellschaft | Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten |
| EA201690938A1 (ru) | 2013-11-05 | 2016-11-30 | Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити | Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания |
| EP3083580A4 (en) * | 2013-12-18 | 2017-06-28 | Harman Finochem Limited | A process for preparation of trelagliptin succinate |
| WO2015092739A1 (en) * | 2013-12-19 | 2015-06-25 | Mylan Laboratories Ltd. | Process for preparation of alogliptin |
| CN104725349A (zh) * | 2013-12-23 | 2015-06-24 | 湖北华世通生物医药科技有限公司 | 阿格列汀盐酸盐多晶a型晶体、其制备方法及生产用途 |
| CN104725350A (zh) * | 2013-12-23 | 2015-06-24 | 湖北华世通生物医药科技有限公司 | 阿格列汀盐酸盐的多晶b型晶体、其制备方法及生产用途 |
| WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
| CN105085475B (zh) * | 2014-05-09 | 2019-05-21 | 上海科胜药物研发有限公司 | 一种合成阿格列汀中间体的方法 |
| CN105315256B (zh) * | 2014-07-07 | 2018-02-06 | 广州朗圣药业有限公司 | 一种适合工业化的高纯度琥珀酸曲格列汀的制备方法 |
| CN105384724A (zh) * | 2014-09-01 | 2016-03-09 | 广东东阳光药业有限公司 | 一种氟代物的晶型及其制备方法 |
| CN105693691A (zh) * | 2014-11-25 | 2016-06-22 | 上海医药工业研究院 | 高纯度曲格列汀的新晶型及其制备 |
| WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
| WO2016139677A1 (en) * | 2015-03-02 | 2016-09-09 | Msn Laboratories Private Limited | Improved process for the preparation of 2-({6-[(3r)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihvdropvrimidin-1(2h)-yl}methyl)benzonitrile and pharmaceutically acceptable salts thereof |
| KR20180006881A (ko) | 2015-03-09 | 2018-01-19 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
| EP3292112B1 (en) | 2015-05-04 | 2019-08-14 | Indoco Remedies Limited | Process for the preparation of alogliptin |
| SG11201708407TA (en) | 2015-05-05 | 2017-11-29 | Pfizer | 2-thiopyrimidinones |
| WO2016202961A1 (en) | 2015-06-17 | 2016-12-22 | H E X A L Aktiengesellschaft | Alogliptin formulation |
| US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| CN108368085B (zh) * | 2016-04-20 | 2021-05-04 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的嘧啶二酮化合物及其药物组合物 |
| CN105837557A (zh) * | 2016-05-05 | 2016-08-10 | 青岛辰达生物科技有限公司 | 一种用于治疗ii型糖尿病的阿格列汀的制备方法 |
| US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
| CN106039298B (zh) * | 2016-07-14 | 2019-11-12 | 广东天普生化医药股份有限公司 | 含有乌司他丁的组合物在制备治疗前列腺癌药物中的用途 |
| CN108072709B (zh) * | 2016-11-18 | 2020-11-24 | 广东东阳光药业有限公司 | 测定琥珀酸曲格列汀原料药中对映异构体含量的方法 |
| EP3551180B1 (en) | 2016-12-09 | 2021-09-29 | Cadila Healthcare Limited | Treatment for primary biliary cholangitis |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| CN108017614A (zh) * | 2018-01-25 | 2018-05-11 | 中国科学院海洋研究所 | Dpp-4抑制剂及其在制备治疗2型糖尿病药物中的应用 |
| CN108558836A (zh) * | 2018-05-14 | 2018-09-21 | 东南大学 | 一类具有双重作用机制的dpp-4抑制剂及其用途 |
| CN110950840B (zh) * | 2019-12-31 | 2022-03-15 | 江苏天和制药有限公司 | 一种琥珀酸曲格列汀的制备方法 |
| JP2023528726A (ja) * | 2020-04-01 | 2023-07-06 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法 |
| US12459954B2 (en) | 2020-04-01 | 2025-11-04 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Crystalline form a of GLP-1 receptor agonist and preparation method therefor |
| CN111646941A (zh) * | 2020-07-17 | 2020-09-11 | 天津科技大学 | 一种磺酰胺类衍生物及其制备方法和应用 |
| TR202022144A1 (tr) | 2020-12-29 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Alogli̇pti̇n i̇çeren farmasöti̇k kompozi̇syonlar |
| TR202022612A2 (tr) | 2020-12-31 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Alogli̇pti̇ni̇n farmasöti̇k kapsül kompozi̇syonlari |
| AU2022204775B2 (en) * | 2021-04-14 | 2023-03-30 | National University Corporation Hokkaido University | Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
| WO2025090919A1 (en) * | 2023-10-25 | 2025-05-01 | Piton Therapeutics, Inc. | Compositions and methods for treating inflammatory bowel disease |
Family Cites Families (322)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB699812A (en) | 1950-11-29 | 1953-11-18 | British Ind Solvents Ltd | Manufacture of substituted pyrimidones |
| DE1249281B (es) | 1963-05-18 | |||
| DE1670912C3 (de) | 1967-08-18 | 1981-06-11 | Bayer Ag, 5090 Leverkusen | Herbizide Mittel auf Basis von 1,2,4-Triazin-5-onen |
| GB1377642A (en) | 1971-01-14 | 1974-12-18 | Koninklijke Gist Spiritus | Penicillanic and cephalosporanic acid derivatives |
| US3960949A (en) | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
| DE2142317A1 (de) | 1971-08-24 | 1973-03-01 | Bayer Ag | Hypnotisches mittel |
| DE2150686A1 (de) * | 1971-10-12 | 1973-04-19 | Basf Ag | 6-amino-uracil-5-carbonsaeurethioamide |
| US3838128A (en) * | 1971-11-22 | 1974-09-24 | American Cyanamid Co | Process for the preparation of certain n-3-substituted-6-(trichloromethyl)uracils |
| BE792206A (es) | 1971-12-02 | 1973-06-01 | Byk Gulden Lomberg Chem Fab | |
| AU5996573A (en) | 1972-09-11 | 1975-03-06 | Commonwealth Scientific And Industrial Research Organisation | Pyridinium salts |
| US3823135A (en) | 1972-12-26 | 1974-07-09 | Shell Oil Co | Pyrimidone herbicides |
| GB1464248A (en) | 1973-11-01 | 1977-02-09 | Ici Ltd | Substituted triazinediones their preparation and use as herbicides |
| DE2361551A1 (de) | 1973-12-11 | 1975-06-19 | Basf Ag | Wasserloesliche azofarbstoffe |
| DE2500024A1 (de) | 1975-01-02 | 1976-07-08 | Basf Ag | Wasserloesliche azofarbstoffe |
| JPS535180A (en) | 1976-07-01 | 1978-01-18 | Sumitomo Chem Co Ltd | Preparation of 3,4-dihydro-2 (1h) quinazoline derivatives |
| DE2720085A1 (de) | 1977-05-05 | 1978-11-16 | Hoechst Ag | Pyrimido(6,1-a)isochinolin-2-on- derivate |
| US4494978A (en) | 1976-12-30 | 1985-01-22 | Chevron Research Company | Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides |
| DE3011809A1 (de) * | 1980-03-27 | 1981-10-01 | Cassella Ag, 6000 Frankfurt | Pyrimidyl-chinazoline, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und ihre verwendung |
| CH657851A5 (de) | 1983-06-28 | 1986-09-30 | Ciba Geigy Ag | Chromogene chinazolonverbindungen. |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| EP0237289A3 (en) * | 1986-03-14 | 1988-07-27 | Takeda Chemical Industries, Ltd. | Pyrazolo [3,4-d] pyrimidine derivatives, their production and use |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| DE3856378T2 (de) | 1987-09-04 | 2000-05-11 | Beecham Group P.L.C., Brentford | Substituierte Thiazolidindionderivate |
| US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
| JPH01143895A (ja) * | 1987-11-30 | 1989-06-06 | Meiji Seika Kaisha Ltd | ピリミジン誘導体 |
| FR2631625B1 (fr) * | 1988-05-17 | 1992-10-16 | Synthelabo | Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique |
| GB8900382D0 (en) | 1989-01-09 | 1989-03-08 | Janssen Pharmaceutica Nv | 2-aminopyrimidinone derivatives |
| US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| IE63502B1 (en) | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
| USRE37979E1 (en) * | 1989-09-29 | 2003-02-04 | Mitsubishi Chemical Corporation | Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof |
| US5814460A (en) | 1990-02-14 | 1998-09-29 | Diatide, Inc. | Method for generating and screening useful peptides |
| US5366862A (en) | 1990-02-14 | 1994-11-22 | Receptor Laboratories, Inc. | Method for generating and screening useful peptides |
| DE69129998T2 (de) * | 1990-02-15 | 1998-12-24 | Takeda Chemical Industries, Ltd., Osaka | Pyrimidindionderivate, deren Herstellung und Verwendung |
| JP3032844B2 (ja) * | 1990-02-15 | 2000-04-17 | 武田薬品工業株式会社 | ピリミジンジオン誘導体 |
| US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| DE4110019C2 (de) | 1991-03-27 | 2000-04-13 | Merck Patent Gmbh | Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
| US5387512A (en) | 1991-06-07 | 1995-02-07 | Merck & Co. Inc. | Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation |
| DE69233671T2 (de) | 1991-10-22 | 2007-10-18 | New England Medical Center Hospitals, Inc., Boston | Inhibitoren der Dipeptidyl-Aminopeptidase vom Typ IV |
| US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
| US5350752A (en) | 1991-12-16 | 1994-09-27 | E. R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
| DE4141788A1 (de) | 1991-12-18 | 1993-06-24 | Merck Patent Gmbh | Imidazopyridine |
| DE4208050A1 (de) * | 1992-03-13 | 1993-09-23 | Bayer Ag | Azolylmethyl-fluorcyclopropyl-derivate |
| DE4305602A1 (de) | 1992-06-17 | 1993-12-23 | Merck Patent Gmbh | Imidazopyridine |
| ZA936492B (en) | 1992-09-10 | 1995-03-02 | Lilly Co Eli | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease. |
| IL106998A0 (en) | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
| JP3481984B2 (ja) * | 1992-12-29 | 2003-12-22 | 武田薬品工業株式会社 | ピリドピリミジン誘導体、その製造方法および用途 |
| US5811281A (en) | 1993-07-12 | 1998-09-22 | Cornell Research Foundation, Inc. | Immortalized intestinal epithelial cell lines |
| US5391541A (en) * | 1993-08-11 | 1995-02-21 | Fmc Corporation | Herbicidal 3-(substituted-benzyl)-1-methyl-6-trifluoromethyluracils |
| US5683966A (en) * | 1993-08-11 | 1997-11-04 | Fmc Corporation | Herbicidal 3-(substituted-benzyl)-1-methyl-6-trifluoromethyluracils |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE4341453A1 (de) | 1993-12-06 | 1995-06-08 | Merck Patent Gmbh | Imidazopyridine |
| KR100233703B1 (ko) | 1994-03-08 | 1999-12-01 | 오츠까 요시미쯔 | 포스폰산 디에스테르 유도체 |
| US5580979A (en) | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| EP0764151A2 (en) | 1994-06-10 | 1997-03-26 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
| US5601986A (en) | 1994-07-14 | 1997-02-11 | Amgen Inc. | Assays and devices for the detection of extrahepatic biliary atresia |
| DE4432860A1 (de) | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| US6265551B1 (en) | 1995-06-01 | 2001-07-24 | Dana-Farber Cancer Institute, Inc. | Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof |
| US6325989B1 (en) | 1995-06-01 | 2001-12-04 | Dana-Farber Cancer Institute, Inc. | Form of dipeptidylpeptidase IV (CD26) found in human serum |
| DE69612698T2 (de) | 1995-06-09 | 2001-12-06 | F. Hoffmann-La Roche Ag, Basel | Pyrimidindion-, Pyrimidintrion-, Triazindion-Derivate als alpha-1-adrenergische Rezeptorantagonisten |
| JPH0928376A (ja) | 1995-07-21 | 1997-02-04 | Ajinomoto Co Inc | 新規ジペプチジルペプチダーゼｉｖとその製造方法 |
| DK1325941T3 (da) | 1995-10-13 | 2005-10-03 | Crompton Vinyl Additives Gmbh | Stabilisatorkombinationer til chlorholdige polymerer |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
| AU744518B2 (en) | 1996-07-01 | 2002-02-28 | Dr. Reddy's Laboratories Limited | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| US5885997A (en) | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| US20030060434A1 (en) | 1997-02-18 | 2003-03-27 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
| AU7381098A (en) | 1997-05-16 | 1998-12-08 | Novo Nordisk Biotech, Inc. | Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same |
| US6011786A (en) * | 1997-06-06 | 2000-01-04 | Ericsson Inc. | Systems and methods for control channel communication in cellular radiotelephone systems |
| EP0897012A1 (en) | 1997-07-05 | 1999-02-17 | Societe Des Produits Nestle S.A. | Cloning of the prolyl-dipeptidyl-peptidase from aspergillus oryzae |
| US6235493B1 (en) | 1997-08-06 | 2001-05-22 | The Regents Of The University Of California | Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue |
| NZ503359A (en) | 1997-09-29 | 2002-02-01 | Point Therapeutics Inc | Method for proliferating haematopoietic cells in vitro in the absence of exogenous cytokines |
| US6485955B1 (en) | 1997-10-06 | 2002-11-26 | The Trustees Of Tufts University | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease |
| US6342611B1 (en) | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
| WO1999025719A1 (en) | 1997-11-18 | 1999-05-27 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Novel physiologically active substance sulphostin, process for producing the same, and use thereof |
| FR2771004B1 (fr) * | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
| US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| DE69833784T2 (de) | 1997-12-16 | 2006-10-19 | Novozymes A/S | Polypeptide mit aminopeptidase-aktivität und für diese codierende nukleinsäuren |
| CA2819705C (en) | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| US20020061839A1 (en) | 1998-03-09 | 2002-05-23 | Scharpe Simon Lodewijk | Serine peptidase modulators |
| FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE19816857A1 (de) * | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| US6355614B1 (en) | 1998-06-05 | 2002-03-12 | Point Therapeutics | Cyclic boroproline compounds |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| EP0967245A1 (de) | 1998-06-26 | 1999-12-29 | Witco Vinyl Additives GmbH | 1,3-disubstituierte 6-Aminouracile zum Stabilisieren von halogenhaltigen Polymeren |
| ES2189300T3 (es) | 1998-06-26 | 2003-07-01 | Crompton Vinyl Additives Gmbh | Nuevos 6-aminouracilos modificados con nh2 como estabilizadores para polimeros halogenados. |
| DE59902320D1 (de) | 1998-06-26 | 2002-09-19 | Crompton Vinyl Additives Gmbh | In 5-Stellung substituierte 6-Aminouracile als Stabilisatoren für halogen-haltige Polymere |
| US6129911A (en) | 1998-07-10 | 2000-10-10 | Rhode Island Hospital, A Lifespan Partner | Liver stem cell |
| DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| US6177437B1 (en) * | 1998-09-04 | 2001-01-23 | University Of Massachusetts Medical Center | Inhibitors of Herpes Simplex virus uracil-DNA glycosylase |
| US20030176357A1 (en) | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| DE19915388A1 (de) * | 1999-04-06 | 2000-10-12 | Witco Vinyl Additives Gmbh | 4-Aminopyrimidinone und Oxazolidino-4-amino-pyrimidinone, Verfahren zu deren Herstellung und ihre Verwendung zum Stabilisieren von halogenhaltigen Polymeren |
| KR20000065885A (ko) * | 1999-04-10 | 2000-11-15 | 최승주 | 항바이러스성 피리미딘다이온 유도체 및 그 제조방법 |
| JP2002542246A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
| WO2000069911A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| DE19926233C1 (de) | 1999-06-10 | 2000-10-19 | Probiodrug Ges Fuer Arzneim | Verfahren zur Herstellung von Thiazolidin |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
| US6340705B1 (en) * | 1999-09-10 | 2002-01-22 | Monsanto Technology, Llc | Use of α-linolenic acid metabolites for treatment or prevention of cancer |
| US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| WO2001023364A1 (en) | 1999-09-28 | 2001-04-05 | Merck Patent Gmbh | Quinazolinones |
| US6447772B1 (en) | 1999-10-01 | 2002-09-10 | Klaire Laboratories, Inc. | Compositions and methods relating to reduction of symptoms of autism |
| US6251391B1 (en) | 1999-10-01 | 2001-06-26 | Klaire Laboratories, Inc. | Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
| WO2001027090A1 (fr) | 1999-10-08 | 2001-04-19 | Meiji Seika Kaisha, Ltd. | DERIVES D'ACIDE BENZOIQUE A SUBSTITUTION m PRESENTANT UN ANTAGONISME CONTRE L'INTEGRINE αvβ¿3? |
| US6261794B1 (en) | 1999-10-14 | 2001-07-17 | Saint Louis University | Methods for identifying inhibitors of methionine aminopeptidases |
| US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| EP1228061A4 (en) | 1999-11-12 | 2004-12-15 | Guilford Pharm Inc | DIPEPTIDYL PEPTIDASE IV INHIBITORS; METHODS OF MANUFACTURE AND USE OF SAID INHIBITORS |
| US20040152745A1 (en) | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| AU2020501A (en) | 1999-12-08 | 2001-06-18 | 1149336 Ontario Inc. | Chemotherapy treatment |
| US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| EP1741447B1 (en) | 2000-01-21 | 2013-09-18 | Novartis AG | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| JP4931314B2 (ja) * | 2000-01-25 | 2012-05-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 性腺刺激ホルモン放出ホルモンレセプタアンタゴニストおよびそれに関連した方法 |
| ES2218381T3 (es) | 2000-01-27 | 2004-11-16 | Eli Lilly And Company | Procedimiento para solubilizar compuestos del peptido 1 de tipo glucagon. |
| US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| JP4088011B2 (ja) * | 2000-02-16 | 2008-05-21 | 株式会社東芝 | 半導体装置及びその製造方法 |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6448045B1 (en) | 2000-03-10 | 2002-09-10 | The Regents Of The University Of California | Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1 |
| US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| CA2400226C (en) | 2000-03-31 | 2007-01-02 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6545170B2 (en) | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| ATE502941T1 (de) | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| US6783757B2 (en) | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
| TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6620821B2 (en) | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| US7078397B2 (en) | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| US6558188B1 (en) * | 2000-06-22 | 2003-05-06 | Hewlett Packard Development Company, L.P. | Impedance controlled electrical connector assembly |
| DE60111849T2 (de) * | 2000-07-04 | 2006-06-08 | Novo Nordisk A/S | Purin-2,6-dione als inhibitoren des enzyms dipeptidyl-peptidase iv (dpp-iv) |
| WO2002002560A2 (en) * | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| JP2002042960A (ja) | 2000-07-25 | 2002-02-08 | Yazaki Corp | コネクタ支持機構 |
| NZ523770A (en) | 2000-08-01 | 2004-11-26 | Pharmacia Corp | Hexahydro-7-1H-azepin-2-YL-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| CA2417942C (en) | 2000-08-04 | 2010-06-29 | Warner-Lambert Company | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
| AU2001277754B2 (en) | 2000-08-10 | 2005-09-29 | Mitsubishi Tanabe Pharma Corporation | Proline derivatives and use thereof as drugs |
| US20020165237A1 (en) | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
| US20020037829A1 (en) | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
| US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| US20020064736A1 (en) | 2000-09-27 | 2002-05-30 | Fuji Photo Film Co., Ltd. | Dye-forming coupler, silver halide photographic light-sensitive material, and method for producing an azomethine dye |
| EP1324995A2 (en) | 2000-09-27 | 2003-07-09 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| TWI290919B (en) | 2000-10-06 | 2007-12-11 | Tanabe Seiyaku Co | Nitrogen-containing five-membered ring compound, a pharmacologically permissible salt thereof and the method for producing the same |
| NZ525443A (en) | 2000-10-12 | 2006-04-28 | Ferring Bv | Dipeptidyl peptidase IV related genes |
| AUPR107800A0 (en) | 2000-10-27 | 2000-11-23 | University Of Sydney, The | Peptide and nucleic acid molecule ii |
| ZA200302590B (en) | 2000-10-27 | 2004-04-02 | Probiodrug Ag | Method for the treatment of neurological and neuropsychological disorders. |
| JP2004518718A (ja) | 2000-10-30 | 2004-06-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 抗糖尿病薬および抗痙攣薬を含んで成る併用療法 |
| WO2002059343A2 (en) | 2000-10-31 | 2002-08-01 | Vanderbilt University | Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor- and vasopeptidase inhibitor-associated angioedema |
| EP1347755A2 (en) | 2000-10-31 | 2003-10-01 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| AU2002225954A1 (en) | 2000-11-08 | 2002-05-21 | The University Of Georgia Research Foundation, Inc. | Dipeptidylpeptidases and methods of use |
| US20020155565A1 (en) | 2000-11-10 | 2002-10-24 | Pilar Garin-Chesa | FAP-activated anti-tumor compounds |
| US20030055052A1 (en) | 2000-11-10 | 2003-03-20 | Stefan Peters | FAP-activated anti-tumor compounds |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
| EP1343763A1 (en) | 2000-11-20 | 2003-09-17 | Bristol-Myers Squibb Company | Pyrodone derivatives as ap2 inhibitors |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| US20040180925A1 (en) | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
| DE10100053A1 (de) | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen |
| IL157179A0 (en) | 2001-02-02 | 2004-02-08 | Takeda Chemical Industries Ltd | Fused heterocyclic compounds |
| TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| EE05735B1 (et) | 2001-02-24 | 2015-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina |
| US6337069B1 (en) | 2001-02-28 | 2002-01-08 | B.M.R.A. Corporation B.V. | Method of treating rhinitis or sinusitis by intranasally administering a peptidase |
| JP4178816B2 (ja) | 2001-03-15 | 2008-11-12 | 田辺三菱製薬株式会社 | 医薬組成物 |
| CZ302848B6 (cs) | 2001-03-19 | 2011-12-14 | Novartis Ag | Kombinace protiprujmového cinidla a derivátu epothilonu |
| EP1385508B1 (en) | 2001-03-27 | 2008-05-21 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| FR2822826B1 (fr) | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE10115921A1 (de) | 2001-03-30 | 2002-10-02 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen |
| US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| GB0109146D0 (en) | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| PE20021080A1 (es) | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| US6918736B2 (en) * | 2001-05-14 | 2005-07-19 | F.R. Drake Company | Method and apparatus for stacking discrete planar objects |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20030060494A1 (en) | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
| US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| WO2003000181A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| US7098239B2 (en) | 2001-06-20 | 2006-08-29 | Merck & Co., Inc | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| US20030135023A1 (en) | 2001-06-27 | 2003-07-17 | Hans-Ulrich Demuth | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| CN1321682C (zh) | 2001-06-27 | 2007-06-20 | 前体生物药物股份有限公司 | 新的二肽基肽酶iv抑制剂和它们作为抗癌药的用途 |
| US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| WO2003002593A2 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| AU2002316437A1 (en) | 2001-06-27 | 2003-03-03 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
| CN1990469A (zh) | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
| US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| WO2003007888A2 (en) | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| TW524754B (en) | 2001-07-24 | 2003-03-21 | Nano Dynamics Inc | Ink supplying cassette having under pressure regulation mechanism |
| JP2005508891A (ja) | 2001-08-13 | 2005-04-07 | プロバイオドラッグ アーゲー | レグマインの不可逆性システインプロテアーゼ阻害剤 |
| EP1285922A1 (en) | 2001-08-13 | 2003-02-26 | Warner-Lambert Company | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| JP2003128551A (ja) | 2001-08-15 | 2003-05-08 | Sankyo Co Ltd | 新規抗糖尿病医薬組成物 |
| US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
| DE10143840A1 (de) | 2001-09-06 | 2003-03-27 | Probiodrug Ag | Neue Inhibitoren der Dipeptidylpeptidase I |
| US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
| KR20040033048A (ko) | 2001-09-14 | 2004-04-17 | 미츠비시 웰파마 가부시키가이샤 | 티아졸리딘 유도체 및 이의 약학적 용도 |
| US6673829B2 (en) | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
| WO2003024965A2 (en) | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| IL160700A0 (en) | 2001-09-21 | 2004-08-31 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| DE60208051T2 (de) | 2001-09-21 | 2006-06-22 | Sanofi-Aventis | 3-substituierte-4-pyrimidonderivate |
| CN101357914A (zh) | 2001-09-21 | 2009-02-04 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| GEP20063767B (en) | 2001-10-01 | 2006-03-10 | Bristol Myers Squibb Co | Spiro-Hydantoin Compounds Useful as Anti-Inflammatory Agents |
| WO2003030946A1 (en) | 2001-10-09 | 2003-04-17 | Novartis Ag | Regulation of insulin production |
| US7064135B2 (en) | 2001-10-12 | 2006-06-20 | Novo Nordisk Inc. | Substituted piperidines |
| TWI301834B (en) | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
| GB0125445D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| US6673815B2 (en) | 2001-11-06 | 2004-01-06 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US20030125304A1 (en) | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
| US20030093697A1 (en) * | 2001-11-13 | 2003-05-15 | Lin Wen Chi | Method for preventing unauthorized persons from entering and using a computer facility |
| US20030089935A1 (en) | 2001-11-13 | 2003-05-15 | Macronix International Co., Ltd. | Non-volatile semiconductor memory device with multi-layer gate insulating structure |
| EP2316470A3 (en) | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
| WO2003045228A2 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
| MXPA04004956A (es) | 2001-11-26 | 2004-08-11 | Schering Corp | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. |
| AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| EP1458374A2 (en) | 2001-12-14 | 2004-09-22 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| US20030171411A1 (en) | 2001-12-21 | 2003-09-11 | Kodra Janos Tibor | Amide derivatives as therapeutic agents |
| US20050063935A1 (en) * | 2001-12-25 | 2005-03-24 | Fumiyasu Hirai | Adsorbent for cytokine, method of adsorptive removal, and apparatus adsorptive removal |
| US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| JP2005516968A (ja) | 2001-12-29 | 2005-06-09 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用 |
| ATE409466T1 (de) | 2002-01-11 | 2008-10-15 | Novo Nordisk As | Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen |
| US7192601B2 (en) * | 2002-01-18 | 2007-03-20 | Walker Edward B | Antimicrobial and sporicidal composition |
| AU2003218969A1 (en) | 2002-02-01 | 2003-09-02 | Probiodrug Ag | Modulation of t lymphocytes using dp iv inhibitors |
| US7101898B2 (en) | 2002-02-01 | 2006-09-05 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
| KR100608414B1 (ko) | 2002-02-13 | 2006-08-02 | 에프. 호프만-라 로슈 아게 | 신규한 피리딘- 및 피리미딘-유도체 |
| RU2285693C2 (ru) | 2002-02-13 | 2006-10-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридина и хинолина, способ их получения, фармацевтическая композиция, применение соединений для лечения заболеваний, ассоциированных с dpp-iv |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| EA007434B1 (ru) | 2002-02-28 | 2006-10-27 | Прозидион Лимитед | Ингибиторы dpiv на основе глутаминила |
| ATE507210T1 (de) | 2002-03-07 | 2011-05-15 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| US20040106802A1 (en) | 2002-04-08 | 2004-06-03 | Torrent Pharmaceuticals Ltd. | Novel compounds and therapeutic uses thereof |
| PL372814A1 (en) | 2002-04-08 | 2005-08-08 | Torrent Pharmaceuticals Ltd. | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| JP2003300977A (ja) * | 2002-04-10 | 2003-10-21 | Sumitomo Pharmaceut Co Ltd | キサンチン誘導体 |
| JP2005531540A (ja) | 2002-04-30 | 2005-10-20 | トラスティーズ・オブ・タフツ・カレッジ | セリンプロテアーゼ阻害剤のスマートプロドラッグ |
| TW200307667A (en) | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| MXPA04011557A (es) | 2002-05-23 | 2005-07-05 | Chiron Corp | Compuestos de quinazolinona sustituida. |
| GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
| WO2003101449A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
| PL374007A1 (en) | 2002-06-06 | 2005-09-19 | Eisai Co, Ltd. | Novel fused imidazole derivative |
| WO2003106416A2 (en) | 2002-06-17 | 2003-12-24 | Smithkline Beecham Corporation | Chemical process |
| WO2003106628A2 (en) | 2002-06-17 | 2003-12-24 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase |
| SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| US20040054171A1 (en) | 2002-07-04 | 2004-03-18 | Jensen Anette Frost | Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative |
| ES2306781T3 (es) | 2002-08-09 | 2008-11-16 | Prosidion Ltd. | Inhibidores de la dipeptidil-peptidasa iv para disminucion de la tasa de aumento cronico de peso. |
| DE60313350T2 (de) * | 2002-08-13 | 2008-01-03 | Warner-Lambert Company Llc | Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer |
| KR101150449B1 (ko) | 2002-08-21 | 2012-06-01 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| US6998502B1 (en) | 2002-09-05 | 2006-02-14 | Sabinsa Corporation | Convenient process of manufacture for difluoromethylornithine and related compounds |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| JP2004123738A (ja) | 2002-09-11 | 2004-04-22 | Takeda Chem Ind Ltd | 徐放性製剤 |
| WO2004031374A2 (en) | 2002-09-18 | 2004-04-15 | Prosidion Ltd. | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
| US20040058876A1 (en) | 2002-09-18 | 2004-03-25 | Torsten Hoffmann | Secondary binding site of dipeptidyl peptidase IV (DP IV) |
| US7262207B2 (en) | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US6869966B2 (en) | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
| KR20050067418A (ko) | 2002-10-18 | 2005-07-01 | 머크 앤드 캄파니 인코포레이티드 | 당뇨병을 치료 또는 예방하기 위한 베타-아미노헤테로사이클릭 디펩티딜 펩티다제 억제제 |
| AU2003301662A1 (en) | 2002-10-21 | 2004-05-13 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| US6995180B2 (en) | 2002-10-23 | 2006-02-07 | Bristol Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| MXPA05005260A (es) | 2002-11-18 | 2005-07-25 | Pfizer Prod Inc | Amidas ciclicas fluoradas que inhiben la dipeptidil peptidasa iv. |
| DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US7109192B2 (en) | 2002-12-03 | 2006-09-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
| US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
| US20050014732A1 (en) | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| KR20050122220A (ko) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| US20040229848A1 (en) | 2003-05-05 | 2004-11-18 | Hans-Ulrich Demuth | Glutaminyl based DP IV-inhibitors |
| WO2004098591A2 (en) * | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| KR20110059664A (ko) | 2003-05-05 | 2011-06-02 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
| WO2004103993A1 (en) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE602004022294D1 (en) | 2003-06-20 | 2009-09-10 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv-inhibitoren |
| AU2004251830B8 (en) | 2003-06-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | Pyrido[2, 1-A]-isoquinoline derivatives as DPP-IV inhibitors |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| WO2005007633A1 (en) * | 2003-07-07 | 2005-01-27 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| CN100376246C (zh) * | 2003-07-07 | 2008-03-26 | 纽罗克里生物科学有限公司 | 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物 |
| KR101139148B1 (ko) * | 2003-07-07 | 2012-04-26 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 고나도트로핀-방출 호르몬 수용체 길항제로서의피리미딘-2,4-디온 유도체 |
| US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| BRPI0413452A (pt) | 2003-08-13 | 2006-10-17 | Takeda Pharmaceutical | composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv |
| WO2005019168A2 (en) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
| WO2005030751A2 (en) | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7238107B2 (en) * | 2003-09-29 | 2007-07-03 | Mcvay Iii Julian Clyde | Consonant pain |
| EP1713780B1 (en) * | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| CN102079743B (zh) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| JP4958774B2 (ja) * | 2004-07-02 | 2012-06-20 | コーセプト セラピューティクス， インコーポレイテッド | 改変されたピリミジン糖質コルチコイドレセプター調節因子 |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| GEP20135838B (en) | 2005-09-14 | 2013-06-10 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors usage at diabetes treatment |
| EP1931350B2 (en) | 2005-09-14 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
| TW200745079A (en) | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
-
2004
- 2004-12-15 CN CN201110004223.1A patent/CN102079743B/zh not_active Expired - Lifetime
- 2004-12-15 EA EA200601701A patent/EA013427B1/ru active Protection Beyond IP Right Term
- 2004-12-15 NZ NZ549716A patent/NZ549716A/en not_active IP Right Cessation
- 2004-12-15 BR BRPI0418639A patent/BRPI0418639B8/pt active IP Right Grant
- 2004-12-15 KR KR1020117011142A patent/KR101071390B1/ko not_active Expired - Lifetime
- 2004-12-15 GE GEAP20049658A patent/GEP20094679B/en unknown
- 2004-12-15 WO PCT/US2004/042209 patent/WO2005095381A1/en not_active Ceased
- 2004-12-15 UA UAA200610844A patent/UA85871C2/uk unknown
- 2004-12-15 CN CN201110005788.1A patent/CN102134229B/zh not_active Expired - Lifetime
- 2004-12-15 CN CN2011100052676A patent/CN102127053A/zh active Pending
- 2004-12-15 CN CN2011100098843A patent/CN102140090A/zh active Pending
- 2004-12-15 CA CA2559302A patent/CA2559302C/en not_active Expired - Lifetime
- 2004-12-15 MX MXPA06010571A patent/MXPA06010571A/es active IP Right Grant
- 2004-12-15 CN CN201110006939.5A patent/CN102134231B/zh not_active Expired - Lifetime
- 2004-12-15 AU AU2004318013A patent/AU2004318013B8/en active Active
- 2004-12-15 CN CN2011100052892A patent/CN102127057A/zh active Pending
- 2004-12-15 CN CN201110006009.XA patent/CN102134230B/zh not_active Expired - Lifetime
- 2004-12-17 JP JP2004382612A patent/JP3895349B2/ja not_active Expired - Lifetime
- 2004-12-17 TW TW093139575A patent/TWI344962B/zh active
- 2004-12-17 TW TW100117512A patent/TWI363757B/zh not_active IP Right Cessation
- 2004-12-21 SI SI200430879T patent/SI1586571T1/sl unknown
- 2004-12-21 DK DK04258153.8T patent/DK1586571T6/en active
- 2004-12-21 AT AT04258153T patent/ATE401320T1/de active
- 2004-12-21 PT PT04258153T patent/PT1586571E/pt unknown
- 2004-12-21 ES ES04258153.8T patent/ES2310704T7/es active Active
- 2004-12-21 EP EP04258153.8A patent/EP1586571B3/en not_active Expired - Lifetime
- 2004-12-21 DE DE602004015067T patent/DE602004015067D1/de not_active Expired - Lifetime
- 2004-12-21 PL PL04258153T patent/PL1586571T6/pl unknown
- 2004-12-21 RS RS20080465A patent/RS50621B2/sr unknown
- 2004-12-28 AR ARP040104929A patent/AR048055A1/es active IP Right Grant
-
2005
- 2005-03-15 US US11/080,992 patent/US7807689B2/en active Active
- 2005-03-15 MY MYPI20051082A patent/MY146290A/en unknown
-
2006
- 2006-06-26 JP JP2006175511A patent/JP4068118B2/ja not_active Expired - Lifetime
- 2006-08-22 IL IL177629A patent/IL177629A/en active Protection Beyond IP Right Term
- 2006-09-05 CR CR8595A patent/CR8595A/es unknown
- 2006-09-15 MA MA29322A patent/MA28469B1/fr unknown
- 2006-09-29 KR KR1020067020496A patent/KR101071389B1/ko not_active Expired - Lifetime
- 2006-10-16 NO NO20064669A patent/NO332232B1/no active Protection Beyond IP Right Term
-
2007
- 2007-07-11 JP JP2007182287A patent/JP4948298B2/ja not_active Expired - Lifetime
- 2007-08-07 US US11/835,295 patent/US7795428B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/929,673 patent/US8329900B2/en active Active
- 2007-10-30 US US11/929,593 patent/US8173663B2/en active Active
- 2007-10-30 US US11/929,737 patent/US7906523B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/929,549 patent/US7781584B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/928,944 patent/US8188275B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/929,482 patent/US8288539B2/en active Active
-
2008
- 2008-10-06 CY CY20081101099T patent/CY1108393T1/el unknown
- 2008-10-14 HR HRP20080509TT patent/HRP20080509T4/hr unknown
-
2012
- 2012-06-18 IL IL220480A patent/IL220480A/en active IP Right Grant
-
2014
- 2014-02-11 NL NL300640C patent/NL300640I2/nl unknown
- 2014-02-12 LU LU92374C patent/LU92374I2/xx unknown
- 2014-02-20 FR FR14C0013C patent/FR14C0013I2/fr active Active
- 2014-02-20 BE BE2014C010C patent/BE2014C010I2/fr unknown
- 2014-02-24 NO NO2014004C patent/NO2014004I1/no not_active IP Right Cessation
- 2014-02-25 CY CY2014013C patent/CY2014013I2/el unknown
- 2014-03-04 HU HUS1400007C patent/HUS1400007I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048055A1 (es) | Derivados de pirimidina como inhibidores de dipeptidil peptidasa | |
| AR045455A1 (es) | Derivados de pirimidina como inhibidores de dipeptidil peptidasa | |
| CO6230984A2 (es) | Inhibidores de cinasa mapk/erk | |
| CO6321274A2 (es) | Compuestos de pirazol acetamida n-sustituida como activadores de glucoquinasa | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR055144A1 (es) | Inhibidor de secrecion acida | |
| AR072936A1 (es) | Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer. | |
| CO6180442A2 (es) | Inhibidores de cinasa mapk/erk | |
| TW200615267A (en) | New bicyclic antibiotics | |
| AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
| AR059826A1 (es) | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble | |
| AR050932A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
| CO6150158A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso | |
| TW200637550A (en) | Thiazole-4-carboxamide derivatives as mGluR5 antagonists | |
| CO6160231A2 (es) | Compuestos de isoindolina 5-substituidos | |
| CR10346A (es) | Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3 | |
| MX2009006286A (es) | Composiciones plaguicidas. | |
| PE20061297A1 (es) | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c | |
| AR071452A1 (es) | Inhibidores de hsp90 | |
| AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
| CO5601027A2 (es) | Derivados de imidazol-4-il-etinil-piridina | |
| NO20081074L (no) | Macrocyclisk inhibitorer av hepatitis C-virus | |
| AR051288A1 (es) | Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |